Telix Pharmaceuticals Limited Logo

Telix Pharmaceuticals Limited

TLPPF

(1.0)
Stock Price

15,90 USD

9.38% ROA

11.29% ROE

117.73x PER

Market Cap.

6.949.782.098,28 USD

3.4% DER

0% Yield

6.63% NPM

Telix Pharmaceuticals Limited Stock Analysis

Telix Pharmaceuticals Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Telix Pharmaceuticals Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (13%), which means it has a small amount of debt compared to the ownership it holds

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 ROE

The stock's ROE indicates a negative return (-253.34%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-53%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (39.3x) suggests it's overvalued, potentially making it an expensive investment.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-23) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Telix Pharmaceuticals Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Telix Pharmaceuticals Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Telix Pharmaceuticals Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Telix Pharmaceuticals Limited Revenue
Year Revenue Growth
1999 0
2000 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 195.142 100%
2019 3.485.000 94.4%
2020 4.680.000 25.53%
2021 4.898.000 4.45%
2022 155.984.000 96.86%
2023 502.547.000 68.96%
2024 755.852.000 33.51%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Telix Pharmaceuticals Limited Research and Development Expenses
Year Research and Development Expenses Growth
1999 0
2000 0 0%
2015 62.000 100%
2016 10.000 -520%
2017 2.977.062 99.66%
2018 18.692.034 84.07%
2019 21.162.000 11.67%
2020 23.085.000 8.33%
2021 34.135.000 32.37%
2022 57.857.000 41%
2023 128.844.000 55.1%
2024 183.132.000 29.64%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Telix Pharmaceuticals Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 0
2000 0 0%
2015 54.000 100%
2016 20.000 -170%
2017 2.457.497 99.19%
2018 8.499.835 71.09%
2019 11.275.000 24.61%
2020 18.006.000 37.38%
2021 34.919.000 48.43%
2022 77.317.000 54.84%
2023 78.985.000 2.11%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Telix Pharmaceuticals Limited EBITDA
Year EBITDA Growth
1999 -578.000
2000 -994.000 41.85%
2015 -16.000 -6112.5%
2016 -14.000 -14.29%
2017 -6.363.921 99.78%
2018 -15.677.907 59.41%
2019 -24.478.000 35.95%
2020 -41.878.000 41.55%
2021 -70.073.000 40.24%
2022 -86.827.000 19.3%
2023 58.437.000 248.58%
2024 62.988.000 7.23%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Telix Pharmaceuticals Limited Gross Profit
Year Gross Profit Growth
1999 0
2000 0 0%
2015 0 0%
2016 0 0%
2017 -3.793 100%
2018 195.142 101.94%
2019 942.000 79.28%
2020 2.656.000 64.53%
2021 2.350.000 -13.02%
2022 94.428.000 97.51%
2023 314.786.000 70%
2024 495.524.004 36.47%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Telix Pharmaceuticals Limited Net Profit
Year Net Profit Growth
1999 -289.000
2000 -497.000 41.85%
2015 -132.000 -276.52%
2016 -44.000 -200%
2017 -6.377.115 99.31%
2018 -13.829.825 53.89%
2019 -27.867.000 50.37%
2020 -44.887.000 37.92%
2021 -80.510.000 44.25%
2022 -104.079.000 22.65%
2023 5.211.000 2097.29%
2024 46.720.000 88.85%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Telix Pharmaceuticals Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 0
2000 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Telix Pharmaceuticals Limited Free Cashflow
Year Free Cashflow Growth
2015 0
2016 0 0%
2017 -6.037.157 100%
2018 -20.747.664 70.9%
2019 -23.801.000 12.83%
2020 1.638.000 1553.05%
2021 -60.667.000 102.7%
2022 -77.831.000 22.05%
2023 13.090.000 694.58%
2024 19.913.000 34.26%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Telix Pharmaceuticals Limited Operating Cashflow
Year Operating Cashflow Growth
2015 0
2016 0 0%
2017 -6.031.515 100%
2018 -20.747.664 70.93%
2019 -23.333.000 11.08%
2020 1.960.000 1290.46%
2021 -59.328.000 103.3%
2022 -63.970.000 7.26%
2023 23.884.000 367.84%
2024 33.609.000 28.94%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Telix Pharmaceuticals Limited Capital Expenditure
Year Capital Expenditure Growth
2015 0
2016 0 0%
2017 5.642 100%
2018 0 0%
2019 468.000 100%
2020 322.000 -45.34%
2021 1.339.000 75.95%
2022 13.861.000 90.34%
2023 10.794.000 -28.41%
2024 13.696.000 21.19%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Telix Pharmaceuticals Limited Equity
Year Equity Growth
1999 0
2000 9.042.000 100%
2017 49.292.795 81.66%
2018 52.904.410 6.83%
2019 70.081.000 24.51%
2020 79.016.000 11.31%
2021 2.158.000 -3561.54%
2022 80.007.000 97.3%
2023 148.911.000 46.27%
2024 403.974.000 63.14%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Telix Pharmaceuticals Limited Assets
Year Assets Growth
1999 0
2000 9.394.000 100%
2017 51.093.728 81.61%
2018 76.708.057 33.39%
2019 102.608.000 25.24%
2020 157.821.000 34.98%
2021 109.813.000 -43.72%
2022 255.353.000 57%
2023 402.222.000 36.51%
2024 745.958.000 46.08%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Telix Pharmaceuticals Limited Liabilities
Year Liabilities Growth
1999 0
2000 352.000 100%
2017 1.800.933 80.45%
2018 23.803.647 92.43%
2019 32.527.000 26.82%
2020 78.805.000 58.72%
2021 107.655.000 26.8%
2022 175.346.000 38.6%
2023 251.224.000 30.2%
2024 341.984.000 26.54%

Telix Pharmaceuticals Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.35
Net Income per Share
0.18
Price to Earning Ratio
117.73x
Price To Sales Ratio
8.84x
POCF Ratio
126.15
PFCF Ratio
298.5
Price to Book Ratio
17.18
EV to Sales
8.71
EV Over EBITDA
82.22
EV to Operating CashFlow
124.56
EV to FreeCashFlow
294.35
Earnings Yield
0.01
FreeCashFlow Yield
0
Market Cap
6,95 Bil.
Enterprise Value
6,85 Bil.
Graham Number
2.19
Graham NetNet
-0.4

Income Statement Metrics

Net Income per Share
0.18
Income Quality
0.93
ROE
0.27
Return On Assets
0.04
Return On Capital Employed
0.07
Net Income per EBT
1.27
EBT Per Ebit
0.73
Ebit per Revenue
0.07
Effective Tax Rate
-0.27

Margins

Sales, General, & Administrative to Revenue
0.13
Research & Developement to Revenue
0.29
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.74
Operating Profit Margin
0.07
Pretax Profit Margin
0.05
Net Profit Margin
0.07

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.16
Free CashFlow per Share
0.07
Capex to Operating CashFlow
0.58
Capex to Revenue
0.04
Capex to Depreciation
3.63
Return on Invested Capital
0.17
Return on Tangible Assets
0.09
Days Sales Outstanding
45.14
Days Payables Outstanding
34.42
Days of Inventory on Hand
47.54
Receivables Turnover
8.09
Payables Turnover
10.6
Inventory Turnover
7.68
Capex per Share
0.09

Balance Sheet

Cash per Share
0,36
Book Value per Share
1,21
Tangible Book Value per Share
0.86
Shareholders Equity per Share
1.21
Interest Debt per Share
0.07
Debt to Equity
0.03
Debt to Assets
0.02
Net Debt to EBITDA
-1.16
Current Ratio
0.99
Tangible Asset Value
0,29 Bil.
Net Current Asset Value
-0,09 Bil.
Invested Capital
152888000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.16
Average Receivables
0,09 Bil.
Average Payables
0,02 Bil.
Average Inventory
25000500
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Telix Pharmaceuticals Limited Dividends
Year Dividends Growth

Telix Pharmaceuticals Limited Profile

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

CEO
Dr. Christian P. Behrenbruch B
Employee
415
Address
55 Flemington Road
North Melbourne, 3051

Telix Pharmaceuticals Limited Executives & BODs

Telix Pharmaceuticals Limited Executives & BODs
# Name Age
1 Mr. Craig Ulrick
Chief Information Officer
70
2 Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA
Co-Founder, MD, Group Chief Executive Officer & Executive Director
70
3 Mr. Darren Patti
Group Chief Operating Officer
70
4 Ms. Kyahn Williamson B.A.
Senior Vice President of Corporate Communications & Investor Relations
70
5 Dr. David N. Cade M.B.A., M.D., MBBS
Group Chief Medical Officer
70
6 Dr. Andreas Kluge M.D., Ph.D.
Chief Medical Advisor
70
7 Mr. Darren Smith B.Bus., FCPA, M.B.A.
Group Chief Financial Officer
70
8 Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)
Chief Scientist
70
9 Mr. Richard Valeix M.B.A.
Chief Executive Officer of Telix Therapeutics
70
10 Ms. Lena Moran-Adams L.L.B.
Group General Counsel
70

Telix Pharmaceuticals Limited Competitors